Janux Therapeutics, Inc. (JANX) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $15.09 (-3.11%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 16, 2026 | Kelsey Goodwin | Piper Sandler | $30.00 | +98.8% |
| Dec 2, 2025 | David Dai | UBS | $57.00 | +277.7% |
| Dec 2, 2025 | Stephen Willey | Stifel Nicolaus | $38.00 | +151.8% |
| Sep 3, 2025 | Brad Canino | Guggenheim | $72.00 | +377.1% |
| Jul 11, 2025 | Sean McCutcheon | Raymond James | $65.00 | +330.7% |
| Dec 3, 2024 | Justin Zelin | BTIG | $100.00 | +562.7% |
| Oct 24, 2024 | David Dai | UBS | $69.00 | +357.3% |
| Sep 5, 2024 | Bradley Canino | Stifel Nicolaus | $70.00 | +363.9% |
| Aug 9, 2024 | George Farmer | Scotiabank | $42.00 | +178.3% |
| May 30, 2024 | George Farmer | Scotiabank | $47.00 | +211.5% |
| May 13, 2024 | Swayampakula Ramakanth | H.C. Wainwright | $63.00 | +317.5% |
| Mar 20, 2024 | Kaveri Pohlman | BTIG | $62.00 | +310.9% |
Top Analysts Covering JANX
JANX vs Sector & Market
| Metric | JANX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.38 | 2.25 | 2.42 |
| Analyst Count | 8 | 8 | 19 |
| Target Upside | +49.8% | +16316.1% | +17.1% |
| P/E Ratio | -7.91 | 3.02 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $16M | $16M | $16M | 9 |
| 2027-03-31 | $11M | $11M | $11M | 4 |
| 2027-06-30 | $12M | $12M | $12M | 3 |
| 2027-09-30 | $12M | $12M | $12M | 3 |
| 2027-12-31 | $13M | $13M | $13M | 3 |
| 2028-03-31 | $3M | $3M | $3M | 2 |
| 2028-06-30 | $9M | $9M | $9M | 5 |
| 2028-09-30 | $17M | $17M | $17M | 4 |
| 2028-12-31 | $24M | $24M | $24M | 4 |
| 2029-12-31 | $112M | $112M | $112M | 11 |
| 2030-12-31 | $233M | $233M | $233M | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-3.31 | $-2.49 | $-1.83 | 11 |
| 2027-03-31 | $-0.66 | $-0.66 | $-0.66 | 3 |
| 2027-06-30 | $-0.69 | $-0.69 | $-0.69 | 5 |
| 2027-09-30 | $-0.73 | $-0.73 | $-0.73 | 3 |
| 2027-12-31 | $-0.76 | $-0.76 | $-0.76 | 6 |
| 2028-03-31 | $-0.81 | $-0.81 | $-0.81 | 4 |
| 2028-06-30 | $-0.76 | $-0.76 | $-0.76 | 6 |
| 2028-09-30 | $-0.70 | $-0.70 | $-0.70 | 4 |
| 2028-12-31 | $-0.70 | $-0.70 | $-0.70 | 7 |
| 2029-12-31 | $-3.49 | $-3.49 | $-3.49 | 10 |
| 2030-12-31 | $-2.82 | $-2.82 | $-2.82 | 5 |
Frequently Asked Questions
What is the analyst consensus for JANX?
The consensus among 8 analysts covering Janux Therapeutics, Inc. (JANX) is Buy with an average price target of $22.60.
What is the highest price target for JANX?
The highest price target for JANX is $100.00, set by Justin Zelin at BTIG on 2024-12-03.
What is the lowest price target for JANX?
The lowest price target for JANX is $30.00, set by Kelsey Goodwin at Piper Sandler on 2026-01-16.
How many analysts cover JANX?
8 analysts have issued ratings for Janux Therapeutics, Inc. in the past 12 months.
Is JANX a buy or sell right now?
Based on 8 analyst ratings, JANX has a consensus rating of Buy (2.38/5) with a +49.8% upside to the consensus target of $22.60.
What are the earnings estimates for JANX?
Analysts estimate JANX will report EPS of $-2.49 for the period ending 2026-12-31, with revenue estimated at $16M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.